OTCMKTS:ALPMY Astellas Pharma Earnings Date & Estimates $14.91 +0.56 (+3.90%) As of 10/15/2026 03:59 PM Eastern Astellas Pharma is estimated to report earnings on Wednesday, November 4, 2026, after market closes. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement Announcement DateNovember 4, 2026TimeAfter Market Closes Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Astellas PharmaAstellas Pharma is expected to post earnings of $0.3990 per share on revenue of $3.80 billion. In the same quarter a year earlier Astellas Pharma reported $0.30 per share on revenue of $3.45 billion. Astellas Pharma last reported on April 27, 2026, posting $0.33 per share and beating the $0.1941 consensus estimate. Astellas Pharma has beaten the consensus EPS estimate in 5 of its last 7 quarters.Consensus EstimatesConsensus EPS$0.3990Expected Revenue$3.80 billionPrior-Year EPS$0.30Prior-Year Revenue$3.45 billionExpected EPS Growth+33.0%Expected Revenue Growth+10.0%Recent Track RecordLast ReportedQ4 2026Last Quarter EPS$0.33 (Beat by +$0.1359)Last Quarter Revenue$3.38 billionEPS Beat Rate5 of last 7 quartersPrepare for the Earnings CallEarnings HistoryCompany ProfileQ4 2026 Earnings ReportQ3 2026 Earnings ReportQ2 2026 Earnings Report Astellas Pharma Earnings FAQ When does Astellas Pharma report earnings? Astellas Pharma (OTCMKTS:ALPMY) is estimated to report earnings on Wednesday, November 4, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it. What is the consensus EPS estimate for Astellas Pharma? Analysts expect Astellas Pharma to post earnings of $0.3990 per share for the quarter. How much revenue is Astellas Pharma expected to report? The consensus revenue estimate for Astellas Pharma is $3.80 billion for the quarter. Astellas Pharma Earnings HeadlinesAstellas Pharma (OTCMKTS:ALPMY) Shares Gap Down - Here's What HappenedOctober 12, 2026 | americanbankingnews.comAstellas Pharma Inc. (OTCMKTS:ALPMY) Stock Short Interest Rises 519.9%October 10, 2026 | americanbankingnews.comA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the eye-popping yields are fueling a boom among everyday investors. Three years ago, barely a dozen of these funds existed - today there are more than 100, holding over $140 billion. These funds trade on the NYSE and NASDAQ and are built to generate monthly income. Some investors are targeting $5,000 a month with roughly one-tenth of the nest egg Wall Street says you need. | Investors Alley (Ad)Head-To-Head Contrast: Heron Therapeutics (NASDAQ:HRTX) vs. Astellas Pharma (OTCMKTS:ALPMY)October 9, 2026 | americanbankingnews.comMizuho Securities Sticks to Their Hold Rating for Astellas Pharma (ALPMF)September 15, 2026 | theglobeandmail.comAstellas Pharma (ALPMF) Receives a Hold from Morgan StanleyAugust 20, 2026 | theglobeandmail.comSee More Astellas Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Astellas Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Astellas Pharma and other key companies, straight to your email. Email Address About Astellas PharmaAstellas Pharma (OTCMKTS:ALPMY) is a Japan-based pharmaceutical company that researches, develops, manufactures and commercializes prescription medicines for patients worldwide. Its portfolio focuses on areas of significant unmet medical need, including oncology, immunology, urology, ophthalmology, neuroscience and medical conditions related to genetic regulation. The company’s products include XTANDI (enzalutamide) for certain prostate cancers, XOSPATA (gilteritinib) for acute myeloid leukemia, PADCEV (enfortumab vedotin-ejfv) for certain urothelial cancers, and PROGRAF (tacrolimus), an immunosuppressant used primarily to help prevent organ rejection following transplantation. Astellas also develops medicines and investigational therapies through internal research and collaborations with biotechnology and pharmaceutical companies. Astellas was established in 2005 through the merger of Yamanouchi Pharmaceutical Co. and Fujisawa Pharmaceutical Co., two Japanese companies with histories dating back several decades. Headquartered in Tokyo, the company serves markets across North America, Europe, Asia and other regions through a global research, development and commercial organization. Naoki Okamura serves as Astellas Pharma’s president and chief executive officer.View Astellas Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin PressureASML Can’t Keep Up With AI Demand—Why That's a Good ThingCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling? Upcoming Earnings HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026)GE Aerospace (10/20/2026)3M (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
